Core Viewpoint - The strategic cooperation agreement between the company and Eli Lilly for drug development in oncology and immunology has been approved and is now effective as of March 24, 2026 [1] Group 1: Strategic Cooperation Agreement - The company announced the signing of a strategic cooperation agreement with Eli Lilly to advance new drug development in oncology and immunology [1] - The agreement has received early approval from the Federal Trade Commission, fulfilling all conditions for its effectiveness [1] - The strategic cooperation agreement officially became effective on March 24, 2026 [1] Group 2: Clarification on Misinterpretations - The company clarified that some media reports incorrectly interpreted the effectiveness of the strategic cooperation agreement as an acquisition of the company [1] - The company emphasized that it has no intention of engaging in any acquisition transactions [1] - Shareholders and potential investors are advised not to rely on market rumors and should refer only to the company's official announcements for information [1]

Group 1 - Morgan Stanley increased its stake in Innovent Biologics (01801) by acquiring 497,823 shares at a price of HKD 82.2756 per share, totaling approximately HKD 40.9587 million [2] - Following the acquisition, Morgan Stanley's total shareholding in Innovent Biologics reached approximately 87,249,700 shares, representing a 5.02% ownership stake [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） （股份代號：1801） 與禮來製藥進行戰略合作的生效及澄清 本公司注意到，部分媒體報導錯誤地將該戰略合作協議的生效解讀為對本公司的 收購。本公司謹此澄清，本公司並未，亦無意進行該等交易。謹此提醒股東及有 意投資者，切勿依賴有關本集團的市場傳聞。有關本集團的任何資訊，應僅以本 公司的官方公告為準。 信達生物製藥 本公告由信達生物製藥（「本公司」或「信達」，連同其附屬公司統稱「本集團」）自 願作出，旨在向本公司股東及有意投資者通報本集團的最新業務動態。 茲提述本公司於2026年2月8日就與禮來製藥簽署戰略合作協議以推動腫瘤學及免 疫學領域新藥研發所作出的公告（「該公告」）。除非上下文另有規定，否則本公告 所用詞彙應與該公告所定義者具有相同涵義。 董事會謹此宣佈，本公司已獲聯邦貿易委員會提前批准，至此，禮來製藥與本公 司之間戰 ...

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by purchasing 497,823 shares at an average price of HKD 82.2756 per share, totaling approximately HKD 40.96 million [1] - Following this transaction, JPMorgan's total holdings in Innovent Biologics rose to 87,249,744 shares, increasing its ownership percentage from 4.99% to 5.02% [1][3] - The transaction date for the increase in holdings was March 19, 2026, and the disclosure was made on March 24, 2026 [2][3]

Core Viewpoint - Morgan Stanley has increased its stake in Innovent Biologics (01801) by acquiring 497,823 shares at a price of HKD 82.2756 per share, totaling approximately HKD 40.9587 million, resulting in a new holding of about 87,249,700 shares, representing 5.02% ownership [1] Group 1 - Morgan Stanley's recent acquisition of shares indicates a bullish sentiment towards Innovent Biologics [1] - The total investment made by Morgan Stanley amounts to approximately HKD 40.9587 million [1] - Following the purchase, Morgan Stanley's total shareholding in Innovent Biologics is now approximately 87.2497 million shares [1]

Core Insights - The article discusses the initiation of a Phase III clinical trial for IBI128, a new generation xanthine oxidase inhibitor, aimed at providing an effective and safe treatment option for millions of gout patients in China [1][6]. Disease Background - Gout is one of the fastest-growing metabolic diseases in China, with a hyperuricemia prevalence rate of 17.7% and a gout prevalence rate of 3.2%, affecting over 177 million people, including tens of millions of gout patients [1][6]. - The disease is increasingly prevalent among younger populations, with nearly 60% of patients aged between 18-35 years, and the average onset age dropping to 48.28 years, linked to high-purine diets, sugary beverage consumption, and sedentary lifestyles [1][6]. Mechanism Innovation - IBI128 is a novel non-purine selective xanthine oxidase inhibitor designed to lower blood uric acid levels by inhibiting the key enzyme xanthine oxidase, aiming for higher selectivity and better safety compared to first-generation and second-generation inhibitors [7][8]. - Current treatments face challenges regarding safety and efficacy, including cardiovascular risks and limitations in clinical application due to hypersensitivity reactions and acute kidney injury risks from high uric acid excretion [2][7]. Phase II Data - The Phase II study (CIBI128A201) results presented at the 2025 Asia Pacific League of Associations for Rheumatology Congress showed an 81% target achievement rate for IBI128 at a 100mg dosage, significantly outperforming the 40mg dose of febuxostat [2][8][9]. - This data indicates that IBI128 has the potential to surpass existing standard treatments in uric acid reduction efficacy [9]. Phase III Study Design - The Phase III study is designed as a randomized, double-blind, multi-center trial, enrolling 600 Chinese patients who meet the 2015 ACR/EULAR gout diagnostic criteria, with a treatment period of one year [3][9]. - The primary endpoint is the proportion of patients achieving blood uric acid levels <360 μmol/L at 24 weeks, with long-term observation to validate treatment benefits [3][9]. Strategic Layout - The company is systematically building its portfolio in the gout and hyperuricemia treatment space, aiming to enhance its competitive edge by offering a comprehensive range of treatment options tailored to different disease stages and patient needs [5][10]. - The ongoing advancements of IBI128 from Phase II to the initiation of Phase III trials are seen as a beacon of hope for gout patients, potentially overcoming existing efficacy and safety limitations of current medications [10].

Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study Accessibility StatementSkip Navigation SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the xanthine oxidase ...

Group 1 - The core viewpoint emphasizes that technological innovation is the driving force for high-quality development, with a focus on original innovation and breakthroughs in key core technologies in the biopharmaceutical sector [1] - The approval of the world's first GCG/GLP-1 dual-target weight loss and blood sugar-lowering drug, developed by Innovent Biologics, marks a significant achievement in original drug development [1] - Innovent Biologics has successfully developed 18 innovative drugs since its establishment in 2011, with 12 included in the national medical insurance directory, benefiting over 6 million patients [2][3] Group 2 - The approval of the first new drug for thyroid eye disease in 70 years fills a significant gap in domestic treatment options, providing new choices for patients [2] - The launch of the first domestically developed IL-23p19 monoclonal antibody by a local company demonstrates ongoing efforts in niche therapeutic areas [2] - Innovent Biologics has invested a total of 30 billion yuan in research and development, establishing three major R&D centers in Shanghai, Suzhou, and the United States, with over 2,000 researchers [3]

Core Viewpoint - The company, Sinopharm (01801.HK), has announced that it will hold a board meeting on March 26, 2026, to consider and approve its annual performance for the year ending December 31, 2025, and to discuss the potential distribution of a final dividend, if any [1] Group 1 - The board meeting is scheduled for March 26, 2026 [1] - The meeting will focus on the annual performance for the year ending December 31, 2025 [1] - The company will also consider the proposal for a final dividend distribution [1]

信達生物製藥 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 中國，香港 2026年3月12日 INNOVENT BIOLOGICS, INC. 於本公告刊發日期，董事會包括主席兼執行董事俞德超博士及執行董事奚浩先生 及張倩女士；及獨立非執行董事Charles Leland Cooney博士、許懿尹女士、Gary Zieziula先生、陸舜博士、陳樹云先生及Stephen A. Sherwin博士。 董事會召開日期 信達生物製藥（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將於 2026年3月26日（星期四）舉行董事會會議，以考慮及批准（其中包括）本公司及其 附屬公司截至2025年12月31日止年度之全年業績及其發佈，並考慮建議派發末期 股息（如有）。 承董事會命 信達生物製藥 主席兼執行董事 俞德超博士 （於開曼群島註冊成立的有限公司） （股份代號：1801） ...